GSK discontinues its chronic cough therapy amid uncertain future

GSK has announced that it is ending development of its chronic cough treatment. The decision marks the conclusion of the program that had been under investigation for several years.

The article does not provide details on the reasons behind the termination, but the move signals a shift in GSK's focus away from this particular respiratory indication.

Other biotech news mentioned in the same briefing includes Sonothera's ultrasound gene‑therapy delivery platform and a controversy surrounding a new Alzheimer’s drug, but those stories are separate from GSK's announcement.

Investors and industry observers will likely watch how GSK reallocates resources following the cessation of this cough program.